Navigation Links
US WorldMeds Announces the Launch of Revonto™ (dantrolene sodium for injection)
Date:7/6/2010

LOUISVILLE, Ky., July 6 /PRNewswire/ -- US WorldMeds is proud to announce the launch of Revonto™ (dantrolene sodium for injection), the first patented scientific advancement in the treatment of malignant hyperthermia (MH).  The time to reconstitute dantrolene sodium for injection has been dramatically reduced to approximately 20 seconds or until the solution is clear.  Revonto™ retains the cost-savings of the original dantrolene sodium for injection product while offering a significant improvement in pharmacotherapy.

"The enhanced reconstitution time is an important and critical scientific improvement to intravenous dantrolene sodium, the only available antidote for the treatment of malignant hyperthermia.  MH is triggered in some patients by certain inhalation anesthetics during surgery.  A rapid response to MH onset is critical because temperatures exceeding 105F degrees and death due to this condition can occur as early as 30 minutes from onset." says Dr. George A. Digenis, Chief Scientific Officer of US WorldMeds.

Fatal and non-fatal liver disorders of an idiosyncratic or hypersensitivity type may occur with dantrolene sodium therapy.  There have been reports of thrombophlebitis following administration of intravenous dantrolene.  There have been rare reports of urticaria and erythema possibly associated with the administration of i.v. dantrolene sodium. For additional information, including the full prescribing information for Revonto™, please visit US WorldMeds' website at www.revonto.com.

For more information on malignant hyperthermia, please visit The Malignant Hyperthermia Association of the United States (MHAUS) website at www.mhaus.org

Revonto™ will be available on GPO contracts as a dropship via your wholesaler/distributor.

For Ordering Information Call: 1.877.411.USWM(8796).

About US WorldMeds

US WorldMeds, LLC, a specialty pharmaceutical company located in Louisville, Kentucky, is committed to developing, licensing, and marketing unique and significant pharmaceuticals that address unmet medical needs. US WorldMeds is committed to using science to make lives better. For more information, please visit www.usworldmeds.com


'/>"/>
SOURCE US WorldMeds
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Bionovo Announces a $15 Million At-The-Market Firm Commitment Financing Agreement
2. Zimmer Holdings Announces Live Audio Webcast and Conference Call of Second Quarter 2010 Results
3. Fougera® Announces First Generic Approval of Adapalene Cream 0.1% (Rx), Equivalent to Differin®
4. Biodel Announces Schedule for Presentations at the 37th Annual Meeting and Exposition of the Controlled Release Society
5. PolyTouch Medical Ltd. Announces the Appointment of Robert D. Fanelli, MD, FACS, FASGE as Medical Advisor
6. Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant Human Stem Cells
7. ProUroCare Medical Announces Offering of Replacement Warrants in Exchange for Early Exercise of Outstanding Warrants
8. MiMedx Group, Inc. Announces Release Date for Second Quarter Results
9. Aeras Global TB Vaccine Foundation Announces Appointment of Accomplished Pharmaceutical Executive as President and CEO
10. Jiangbo Pharmaceuticals Announces the Appointment of New Chief Executive Officer
11. Sysmex America Announces Executive Leadership Changes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)...   Pulmatrix, Inc ., (NASDAQ: PULM ... announced today that it was added to the Russell ... comprehensive set of U.S. and global equity indexes on ... milestone for Pulmatrix," said Chief Executive Officer Robert ... progress in developing drugs for crucial unmet medical needs, ...
(Date:6/23/2016)... Any dentist who has made an implant supported ... Many of them do not even offer this as a ... laboratory costs involved. And those who ARE able to offer ... high cost that the majority of today,s patients would not ... Zadeh , founder of Dental Evolutions Inc. and inventor of ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... ... issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the ... several important health care topics including advance care planning, healthcare costs and patient ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe ... from the David Geffen School of Medicine at UCLA. He trained in Internal Medicine ... his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set of ... or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, Serenity ... event. , Trauma sufferers tend to feel a range of emotions, from depression, guilt, ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty Network, ... M. Weintraub as a prominent plastic surgeon and the network’s newest partner. ... the most handsome men, look naturally attractive. Plastic surgery should be invisible.” He ...
Breaking Medicine News(10 mins):